Treatment of patients with progression of cerebral medulloblastoma in adults
https://doi.org/10.33667/2078-5631-2022-26-41-44
Abstract
The aim of this work was to evaluate the results of treatment of patients with progression of primary cerebral medulloblastomas in adults. The study included 10 patients with progression of brain medulloblastomas, who had been treated since 2016 to 2021 treatment was carried out on the basis of the Chelyabinsk Regional Centre for Oncology and Nuclear Medicine. The mean age of patients with relapse of brain medulloblastoma was 27.14 ± 4.30 years (from 23 to 35 years). Males predominated (n = 9) and in one case a relapse was recorded in a woman. The median time to relapse was 56 months (12 to 144 months). According to the method of recurrence treatment, in 3 cases, for recurrence, repeated stereotaxic radiation therapy was performed using the CyberKnife device with ROD = 7 Gy in three fractions up to SOD = 24 Gy, the remaining 7 patients underwent chemotherapy according to the PCV scheme. The median overall survival was 130 months (CI: 59.6–200.3), 1-year overall survival rates were 100 %; 5-year-old – 76.7 %; 7-year-old – 53.7 %. When analyzing the relationship between the size of the residual tumor and survival rates, we found that with a residual tumor size of more than 1.5 cm, the 5-year overall survival rate was significantly lower compared to a small residual tumor – 54 % and 77 % respectively (p = 0.005). The best indicators of method-specific survival were observed during polychemotherapy: 27 months compared to 21 months when performing stereotactic radiation therapy (p = 0.782).
About the Authors
M. M. Sarycheva
South Ural State Medical University; Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine
Russian Federation
Russian Federation
Sarycheva Marina M., PhD Med, assistant at Dept of Oncology, Radiation Diagnostics and Radiation Therapy; radiotherapist
SPIN: 6116–6776
Chelyabinsk
A. V. Vazhenin
South Ural State Medical University
Russian Federation
Russian Federation
Vazhenin Andrey V., DM Sci (habil.), professor, academician of RAS, acting rector, head of Dept of Oncology, Radiation Diagnostics and Radiation Therapy
Chelyabinsk
R. Yu. Karabut
Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine
Russian Federation
Russian Federation
Karabut Radmila Yu., radiotherapist
Chelyabinsk
References
1. Franchino F, Morra I, ForniM, et al. Medulloblastoma in adults: an analysis of clinico-pathological, molecular and treatment factors. J Neurosurg Sci. 2021. DOI: 10.23736/S0390–5616.21.05548-X.
2. Coltin H, Sundaresan L, Smith K, et al. Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathol2021; 142 (5): 859–871. DOI: 10.1007/s00401–021–02358–4.
3. Rebecca M, Sabine L, Beate Timmermann, et al. Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment. Cancers (Basel). 2021; 14 (1): 126. DOI: 10.3390/cancers14010126.
4. Remke M, Hielscher T, Northcott P A. Adult medulloblastoma comprises three major molecular variants. J. Clin. Oncol 29 (19): 2717–2723. https://doi.org/10.1200/JCO.2011.34.9373
5. Majd N, Penas-Prado M. Updates on Management of Adult Medulloblastoma. Curr Treat Options Oncol. 2019. 20 (8): 64. DOI: 10.1007/s11864–019–0663–0.
6. Franceschi E, Minichillo S, Mura A, et al. Adjuvant chemotherapy in average-risk adult medulloblastoma patients improves survival: a long term study. BMC Cancer. 2020; 20 (1): 755. DOI: 10.1186/s12885–020–07237-x.
7. Kann B, Lester-Coll N, Park H, et al. Neuro Oncol. 2017 Feb 1; 19 (2): 259–269. DOI: 10.1093/neuonc/now150.
8. Richardson S, Hill R, Kui C, et al. Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. Neuro-Oncology 2021, noab178.
9. Hill R, Richardson S, Schwalbe E, Hicks D, et al. Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study. Lancet Child Adolesc Health. 2020 Dec; 4 (12): 865–874. DOI: 10.1016/S2352–4642 (20)30246.
10. Cuccia F, Mortellaro G, Ognibene L, Craparo G, Lo Casto A, Ferrera G. Cuccia F, et al. Salvage Re-irradiation Options in Adult Medulloblastoma: A Case Report and Review of the Literature. In Vivo. 2020 May-Jun; 34 (3): 1283–1288. DOI: 10.21873/invivo.11903.
11. Sabel M. Relapse patterns and outcome after relapse in standard risk medullo-blastoma: A report from the HIT-SIOP-PNET4 study. Journal of Neuro-Oncology v. 129, p. 515–524 (2016).
12. Sabel M, Fleischhack G, Tippelt S, Gustafsson G, et al. Relapse patterns and outcome after relapse in standard risk medulloblastoma: A report from the HIT-SIOP-PNET4 study. J. Neuro-Oncol. 2016, 129, 515–524.
13. Wetmore C., Herington D., Lin T., Onar-Thomas A., Gajjar A. Merchant T. E. Reir-radiation of recurrent medulloblastoma: Does clinical benefit outweigh risk for toxicity? Cancer 2014, 120, 3731–3737,
14. Paul S, Sesikeran B, Patro K, Bhattacharya K, Palkonda V. Re-irradiation in central nervous system tumors. J. Curr. Oncol. 2018, 1, 40–42.
15. Gupta T, Maitre M, Sastri GJ, et al. Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk-stratification, and molecular subgrouping. J Neurooncol 2019. 144 (2): 283–291. DOI: 10.1007/s11060–019–03225–9.
16. Cuccia F, Mortellaro G, Ognibene L, Craparo G, Lo Casto A, Ferrera G. Cuccia F, et al. Salvage Re-irradiation Options in Adult Medulloblastoma: A Case Report and Review of the Literature. In Vivo. 2020 May-Jun; 34 (3): 1283–1288. DOI: 10.21873/invivo.11903.
17. Napieralska A, Brąclik I, Radwan М, et al. Radiosurgery or hypofractionated stereotactic radiotherapy after craniospinal irradiation in children and adults with medulloblastoma and ependymoma. Childs Nerv Syst. 2019; 35 (2): 267–275. DOI: 10.1007/s00381–018–4010.
18. Abe M, Tokumaru S, Tabuchi K, Stereotactic radiation therapy with chemotherapy in the management of recurrent medulloblastomas. Pediatr Neurosurg 2006. 42 (2): 81–88. DOI: 10.1159/000090460.
19. Alba A. Brandes., Franceschi E., Tosoni A., et al. Long-term results of a prospective study on the treatment of medulloblastoma in adults. October 2007. https://doi.org/10.1002/cncr.23003.
20. Aykan M, Erturk I, Acar R, et al. High-dose Chemotherapy Response in Adults with Relapsed/Refractory Small Round Cell Tumours. J Coll Physicians Surg Pak. 2022 Jan; 32 (1): 51–56. DOI: 10.29271/jcpsp.2022.01.51.
Review
For citations:
Sarycheva M.M., Vazhenin A.V., Karabut R.Yu. Treatment of patients with progression of cerebral medulloblastoma in adults. Medical alphabet. 2022;(26):41-44. (In Russ.) https://doi.org/10.33667/2078-5631-2022-26-41-44
Views:
294
Email this article 